RhoC、ROCKI在宫颈癌前病变和宫颈癌中的表达及意义

目的：探讨RhoC和ROCKⅠ基因在不同等级宫颈上皮内瘤变（cervical intraepithelial neoplasia,CIN）和宫颈癌中的表达情况及二者与宫颈癌发生的相关性.方法：采用免疫组化的方法检测慢性炎症28例、CINⅠ25例、CINⅡ28例、CINⅢ28例、宫颈癌27例中RhoC和ROCKⅠ基因的表达情况.结果：RhoC和ROCKⅠ在CINⅡ、CINⅢ和宫颈癌中的表达水平显著高于CINⅠ和慢性炎症,病变程度越重,表达水平越高,差异有统计学意义（P＜0.01）.RhoC和ROCKⅠ的表达在CINⅡ及以上病变中成正相关（rs=0.605,P＜0.001）.结论：RhoC在表达水平较高时可能通过ROCKⅠ促进宫颈癌前病变的进展和宫颈癌的发生,RhoC/ROCKⅠ可能成为早期治疗的新靶点.宫颈组织中RhoC的表达水平有助于完善宫颈病变患者的治疗方案和评估宫颈病变的癌变风险.

Expression and Significance of RhoC and ROCK I in Precancerous Lesions of Uterine Cervix and Cervical Cancer

Objective： To explore the expressions of RhoC and ROCK I in cervical intraepithelial neoplasia （CIN） and cervical cancer as well as their relationship with the genesis of cervical cancer. Methods： The expressions of RhoC and ROCK I in cervical cancers （ n = 27 ）, CIN m （ n = 28 ）, CIN II （ n = 28 ）, CIN I （ n = 25 ） and chronic inflammations （ n = 28 ） were detected by immunohisto-chemistry. Results ： The expressions of RhoC and ROCK I in CIN II , CIN III and cervical cancer were significantly higher than that of CIN I and chronic inflammation （P 〈0. 01 ）. The severer the cervical lesion was, the higher expression level of Rhoc and ROCK I. And the expression level of RhoC was of positive correlation with that of ROCK I in CIN 1I and above stages（rs --0. 605, P 〈0. 001 ）. Conclusion： RhoC/ROCK I pathway may play an important role in the progression of precancerous lesions of uterine cervix and the genesis of cervical cancer when RhoC expression is at a high level. RhoC/ROCK I would be a new target of clinical therapy. RhoC expression may be a good marker for improving treatment scheme and evaluating the risk of canceration.